Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
|Videos|August 9, 2021
What can be learned from a clinical trial of standard vs expanded cultures to diagnose UTI
Author(s)Urology Times staff
“What was surprising to us was that in both arms, about a third of the women really didn't have a urinary tract infection,” says Elizabeth R. Mueller, MD, MSME.
Advertisement
In this video, Elizabeth R. Mueller, MD, MSME, shares the take-home message from the Journal of Urology study, “A Randomized Clinical Trial of Standard Versus Expanded Cultures to Diagnose Urinary Tract Infections in Women,” for which she served as a study author. Mueller is a professor of urology and obstetrics/gynecology and division director of Female Pelvic Medicine and Reconstructive Surgery at Loyola University Medical Center, Chicago, Illinois.
Advertisement
Related to this article
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Daniel Heng, MD, discusses final LITESPARK-011 results, including sustained PFS benefit with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5